Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (101-110 of 150) with videos related to

Pageof 15
Sort By:
Antiviral Therapy|February 5, 2008
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutationAndrea Antinori, Maria Paola Trotta, Patrizia Lorenzini, et al.
Journal of the International AIDS Society|November 14, 2014
Patient preferences for characteristics of antiretroviral therapies: results from five European countriesBrian Gazzard, Shehzad Ali, Axel Muhlbacher, et al.
Antiviral Research|October 21, 2019
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the differenceAndrea Giacomelli, Alessia Lai, Marco Franzetti, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2016
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort studyEugenia Quiros-Roldan, Elena Raffetti, Francesco Castelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 14, 2015
Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter StudyElena Raffetti, Francesco Donato, Chiara Pezzoli, et al.
BMC Public Health|August 26, 2016
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER CohortElena Raffetti, Maria Concetta Postorino, Francesco Castelli, et al.
International Journal of Antimicrobial Agents|January 28, 2023
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO RegistryFrancesco Saladini, Federica Giammarino, Franco Maggiolo, et al.
The Lancet. HIV|May 10, 2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialHans-Jürgen Stellbrink, José R Arribas, Jeffrey L Stephens, et al.
International Journal of Antimicrobial Agents|February 16, 2019
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitorsGaetana Sterrantino, Vanni Borghi, Anna Paola Callegaro, et al.
BMC Infectious Diseases|March 17, 2017
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohortMaria Concetta Postorino, Mattia Prosperi, Emanuele Focà, et al.
Pageof 15

Showing results (101-110 of 150) with videos related to

Sort By:
Pageof 15
Antiviral Therapy|February 5, 2008
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutationAndrea Antinori, Maria Paola Trotta, Patrizia Lorenzini, et al.
Journal of the International AIDS Society|November 14, 2014
Patient preferences for characteristics of antiretroviral therapies: results from five European countriesBrian Gazzard, Shehzad Ali, Axel Muhlbacher, et al.
Antiviral Research|October 21, 2019
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the differenceAndrea Giacomelli, Alessia Lai, Marco Franzetti, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2016
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort studyEugenia Quiros-Roldan, Elena Raffetti, Francesco Castelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 14, 2015
Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter StudyElena Raffetti, Francesco Donato, Chiara Pezzoli, et al.
BMC Public Health|August 26, 2016
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER CohortElena Raffetti, Maria Concetta Postorino, Francesco Castelli, et al.
International Journal of Antimicrobial Agents|January 28, 2023
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO RegistryFrancesco Saladini, Federica Giammarino, Franco Maggiolo, et al.
The Lancet. HIV|May 10, 2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialHans-Jürgen Stellbrink, José R Arribas, Jeffrey L Stephens, et al.
International Journal of Antimicrobial Agents|February 16, 2019
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitorsGaetana Sterrantino, Vanni Borghi, Anna Paola Callegaro, et al.
BMC Infectious Diseases|March 17, 2017
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohortMaria Concetta Postorino, Mattia Prosperi, Emanuele Focà, et al.
Pageof 15